Related Experiment Video
Updated: May 25, 2026
04:53
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
A flexible multi-stage design for phase II oncology trials
1Division of Biostatistics and Bioinformatics, University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA. mttan@som.umaryland.edu
Pharmaceutical Statistics
|February 14, 2012
Summary
This study introduces a unified sequential method for Phase II clinical trials, optimizing multi-stage designs to efficiently assess new cancer therapies and minimize patient exposure to ineffective treatments.
Area of Science:
- Clinical Trials Methodology
- Biostatistics
- Oncology Drug Development
Background:
- Phase II trials are critical for evaluating new cancer therapies and treatment feasibility.
- Traditional designs often use two-stage procedures, but multi-stage designs offer greater flexibility.
- Current methods for optimizing Phase II trials are often disparate, lacking a unified approach.
Purpose of the Study:
- To present a unified, fully sequential approach for Phase II clinical trial design.
- To demonstrate how this method optimizes multi-stage designs for various activity levels.
- To provide tools for minimizing patient exposure to ineffective therapies and determining minimum required sample sizes.
Main Methods:
- Utilizes the sequential conditional probability ratio test for a fully sequential procedure.
- Applies exact binomial distribution for all computations.
- Derives optimized multi-stage designs and calculates the probability of discordance for early stopping decisions.
Main Results:
- The sequential conditional probability ratio test offers a unified approach to address multiple Phase II trial needs.
- Enables optimized multi-stage designs for low or high drug activity.
- Identifies minimum patient numbers for further study assessment and adjusts for interim analyses.
Conclusions:
- A single, unified sequential method can effectively manage multiple objectives in Phase II cancer trials.
- This approach enhances decision-making in drug development by providing probabilities of discordance.
- Optimized designs lead to more efficient and ethical evaluation of novel therapies.
Related Concept Videos
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:16Crossover Experiments
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:15Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...